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Abstract Gap junctions (GJ) represent a cellular
communication system known to influence neuronal
differentiation and survival. To assess a putative role of
this system for neural effects of tamoxifen (TAM) and
raloxifene (RAL), we used the human teratocarcinoma
cell line NTera2/D1, retinoic acid (RA)-dependent
neuronal differentiation of which is regulated by gap
junctions formed of connexin43 (Cx43). As demon-
strated by Western blot analysis, concentrations above
1 µmol/l for TAM, and 0.1 µmol/l for RAL lead to a
temporary time- and concentration-dependent increase
in Cx43 immunoreactivity, which reached a peak for
TAM after 1 day and for RAL after 2 days. Immuno-
cytochemical stainings revealed the increase in Cx43
immunoreactivity to result from an accumulation in
intracellular compartments such as the Golgi apparatus
or lysosomes. In addition, TAM and RAL were able to
prevent the RA-dependent decrease of Cx43 immuno-
reactivity in NTera2/D1 cells, normally observed during
neuronal differentiation. This suggested a suppression
of neuronal differentiation to result from these sub-
stances. According to this, treatment of NTera2/D1 cells
with 10 µmol/l TAM or RAL during weeks 1 and 2 of a
6 weeks RA-driven differentiation schedule impaired,
whereas treatment during weeks 5 and 6 did not impair,
neuronal differentiation ofthese cells.ModulationofGJ
coupling between NTera2/D1 cells by TAM and RAL
seemsthereforetoperturbearlyneuronaldifferentiation,
whereas differentiated neurons in the mature brain seem
to be not affected. These effects could be of importance
for actions of TAM and RAL on early embryonic steps
of nervous system formation.
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Introduction
Tamoxifen (TAM) and raloxifene (RAL) are nonste-
roidal selective estrogen receptor modulators widely
used for the treatment of estrogen responsive breast
cancer as well as for breast cancer prophylaxis in
w o m e na th i g hr i s ko fd e v e l o p i n gt h i sd i s e a s e
(Wickerham et al. 2009). Both drugs are also used
to prevent osteoporosis in postmenopausal women
(Reginster and Devogelaer 2006), and high-dose
treatment with TAM in combination with radiation
therapy is able to inhibit proliferation in glioblastoma
cells (da Rocha et al. 1999). Besides their specific
actions on bone and tumor cells, both substances are
known to affect also other organ systems such as liver
(Williams et al. 1993), endometrium (Fisher et al.
1994), and the brain (Eberling et al. 2004; Yaffe et al.
2005; Palmer et al. 2008; Collins et al. 2009). In
addition, TAM has been shown to also affect fetal
development, since prenatal exposure results in
craniofacial malformations as well as deviations in
the female reproductive tract (Berger and Clericuzio
2008; Cunha et al. 1987). Also high doses of RAL are
known to elicit teratogenic effects resulting in reduced
fetal growth and organ malformations, i.e., of heart
and kidney (Byrd and Francis 1998). Also impaired
neurogenesis has been demonstrated for TAM, since
in rats treated with TAM during late fetal and early
postnatal phases of development revealed impaired
hippocampal morphology (Nobakht et al. 2009). The
present study was designed to clarify in vitro, whether
TAM and RAL affect also neuronal differentiation of
human-derived cells and if so, whether intercellular
communication by gap junctions (GJ) could be
involved in these processes.
GJ provide a communication pathway with a well-
known impact on cell differentiation and survival
during development and in the adult organism (Revel
1986; Guthrie and Gilula 1989; Wei et al. 2004). GJ
are assemblies of membrane channels connecting the
cytoplasm of neighboring cells. A functional GJ
channel is thereby established by docking of two
hemichannels, provided by each of the adjacent cells.
Every hemichannel consists of a hexagonal array of
six connexin (Cx) proteins, surrounding a central
channel pore, allowing the propagation of second
messengers, nutrients, and other metabolic products
with molecular weights of less than 1 kDa (Meşee t
al. 2007). Cx belong to a family of more than 20 GJ
proteins, which differ with regard to functional
parameters like permeability and open probability,
and are expressed in a tissue and cell-type-specific
manner (Söhl and Willecke 2004). Functionality of
GJ channels is regulated by different ways, including
changes in expression levels or levels of membrane
integration as well as epigenetic modifications such as
a step-wise phosphorylation (Solan and Lampe 2009).
During neuronal differentiation, GJ coupling reveals a
progressive decrease from extensive coupling be-
tween early neuronal precursor cells, towards a more
restricted coupling pattern or an entire lack of
coupling between differentiated neurons (Sutor and
Hagerty 2005; Bruzzone and Dermietzel 2006). The
corresponding GJ protein is Cx43, which is highly
expressed in neuronal precursor cells and gradually
decreases during progredient neuronal differentiation.
A cell culture model for neuronal differentiation is
NTera2/D1 cells, a line of human teratocarcinoma
cells, derived from a lung metastasis of a testicular
germ cell tumor (Andrews 1984). NTera2/D1 cells
share some common properties with early embryonic
stem cells, and can be differentiated into neurons and
glial cells by treatment with retinoic acid (RA;
Pleasure and Lee 1993). Undifferentiated NTera2/D1
cells are coupled by GJ, and as an early event during
RA-induced neuronal differentiation, expression of
Cx43, the corresponding GJ protein, is diminished
(Bani-Yaghoub et al. 1997; Boucher and Bennett
2003). On the other hand, inhibition of GJ coupling
between NTera2/D1 cells has also been shown to
abolish their RA-dependent neuronal differentiation
(Bani-Yaghoub et al. 1999). Therefore, GJ are first
of major importance for the induction of early
neuronal differentiation of NTera2/D1 cells, and are
later downregulated during their neuronal differen-
tiation. NTera2/D1 cells have already earlier been
used to test neurotoxicity of several substances with
different levels of embryotoxicity such as acrylam-
ide, lithium, valproic acid, and hydroxyurea, and
were found to detect neurotoxic substances in a
highly reliable manner (Woehrling et al. 2007,
2010; Hill et al. 2008). Due to these properties and
to the central role of GJ-mediated intercellular
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NTera2/D1 cells were chosen here as a model system
to address the question for a putative role of gap
junctions in mediating effects of TAM and RAL on
early neuronal differentiation.
Materials and methods
Cell culture and neuronal differentiation
of NTera2/D1 cells
NTera2/D1 cells were obtained from the German
Collection for microorganisms and cell cultures (http://
www.dsmz.de). Cells were seeded in Dulbecco's
modified Eagle’s medium, supplemented with 10%
α-minimal essential medium (α-MeM), 10% fetal
bovine serum, 100 U/ml penicillin, 100 µg/ml
streptomycin, 2 mmol/l L-glutamine, and 1 mmol/l
sodium pyruvate (all from http://www.invitrogen.com)
on standard polystyrene cell culture flasks (http://www.
sarstedt.com), with the flasks being maintained in a
humidified incubator at 37°C under 5% CO2.O n c ea
week, subconfluent monolayers of NTera2/D1 cells
were split by incubation with Trypsin–EDTA (http://
www.invitrogen.com), and 100,000 cells were seeded
on cell culture flasks for maintenance culture. Of the
remaining cells, 2 million were seeded either on six-
well plates for protein extraction, or on 12-mm
coverslips in a 24-well plate for immunocytochemistry.
For scrape loading, cells were plated at the same
density on 100-mm cell culture grade Petri dishes
(www.sarstedt.com). Stock solutions of either TAM,
RAL, or RA were prepared in cell culture grade
dimethylsulfoxide (DMSO, http://www.merck.com)
and dissolved in cell culture medium at concentrations
as indicated in the text. All controls were supplied with
the corresponding amount of vehicle (DMSO, http://
www.merck.com). In order to minimize differences in
cell density, cells were treated according to the
following schedule: for a 1-day treatment, cells were
exposed at day 6, for a 2-days treatment at day 5, and
for a 4-day treatment at day 3 and 5 after plating. All
cells were harvested or fixed on day 7. For neuronal
differentiation, 2 million of NTera2/D1 cells were
seeded on 12-mm coverslips in a 24-well plate
followed by 6 weeks treatment with 10 µmol/l RA.
To test for early and late effects of TAM and RAL on
neuronal differentiation, cells were additionally treated
with 10 µmol/l of TAM or RAL either during weeks 1
and 2 or weeks 5 and 6 of a 6-week differentiation
schedule.
Western blot analysis
Ten micrograms of total cellular protein dissolved in
electrophoresis sample buffer (0.5 mmol/l TRIS/HCl,
pH 6.8, 2% sodium dodecyl sulfate (SDS) (w/v), 10%
glycerol (v/v), 5% β-mercaptoethanol (v/v), and
0.001% bromophenol blue (w/v)), was size fractionated
by 8.5% SDS-polyacrylamide gel electrophoresis.
Proteins were blotted onto polyvinylidene difluoride
membranes (http://www.carl-roth.de), which were then
blocked for 1 h at 4°C in 3% (w/v) nonfat dry milk
dissolved in TRIS-buffered saline (TBS). Blots were
probed with antibodies directed to either Cx43 (rabbit
polyclonal, dilution 1:2,500; http://www.invitrogen.
com), or βIII-tubulin (rabbit polyclonal, 1:2,500;
http://www.sigmaaldrich.com), diluted in TBS with
3% nonfat dry milk. After washing, primary antibodies
were detected by incubation with a peroxidase-
conjugated goat anti-rabbit secondary antibody (dilu-
tion 1:20,000; http://www.piercenet.com), which was
visualized by exposing CLXposure X-ray films (http://
www.piercenet.com), during the application of an
enhanced chemiluminescence (ECL) detection solution
(ECL Western Blotting Substrate; http://www.pierce
net.com). After development and fixation, the films
were scanned, and the ECL-signals were quantified
densitometrically, using the Metamorph image analysis
software (www.moleculardevices.com). For loading
control, blots were stripped for 15 min in 0.1 mol/l
NaOH, and reprobed with an antibody directed to β-
actin (mouse monoclonal, dilution 1:5,000; http://
www.sigmaaldrich.com). Detection was performed as
described above, using a peroxidase-conjugated rabbit
anti-mouse secondary antibody (dilution 1:20,000;
http://www.piercenet.com). Mean values and standard
deviations of the signal intensities of four independent
experiments were calculated and tested for significance
by Student’st w o - t a i l e dt test.
Immunocytochemistry
Cells on 12-mm glass cover slips were fixed for 10 min
by 4% paraformaldehyde (PFA) in phosphate-buffered
saline (PBS). After washing and permeabilization with
PBS/Tween-20 they were blocked with 0.5% goat
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4°C with primary antibodies directed to either Cx43
(rabbit polyclonal, 1:400; http://www.invitrogen.com)
or βIII-tubulin (rabbit polyclonal, 1:100; http://www.
sigmaaldrich.com). For visualization, fixed cells were
incubated sequentially with a biotinylated goat anti-
rabbit secondary antibody (dilution 1:400; http://www.
sigmaaldrich.com) ,f o l l o w e db yac o m p l e xo f
fluorescein-isothiocyanate and streptavidin (dilution
1:400; http://www.sigmaaldrich.com). Cover slips were
then mounted on glass slides using an aqueous
fluorescence mounting medium (http://www.dako.
com). Microscopic evaluation was performed with an
Axiophot microscope (http://www.zeiss.com)e q u i p p e d
with epifluorescence, at standardized illumination
conditions, and camera settings.
Scrape loading
Forscrapeloading,confluent monolayersofNTera2/D1
cells treated as indicated in the text, were washed three
times with sterile saline (0.9% NaCl), and were covered
with 1 mg/ml Lucifer yellow (LY) CH (http://www.
sigmaaldrich.com) in sterile saline at 37°C. To start dye
loading, four cuts were set in the monolayer with a
scalpel blade. After 2 min the dye solution was
removed, followed by three washing steps using sterile
saline. Four minutes after setting the scrapes, dye
spreading was stopped by fixing the cells for 10 min
with an ice-cold solution of 1% PFA in sterile saline.
After three washes with sterile saline, dye spreading
was documented photographically, using an inverse
microscope equipped with epifluorescence (http://
www.zeiss.com). Again, all illumination conditions
and camera settings were standardized. For statistical
evaluation, distances of dye spreading were measured
at 10 locations in each of the four scrapes in four
independently treated Petri dishes (n=40). Significance
was analyzed by Student’st w o - t a i l e dt test.
Results
Both TAM and RAL cause a temporary upregulation
of Cx43 in NTera2/D1 cells and a shift in subcellular
localization
Phase-contrast images of NTera2/D1 cells treated for
2 days with either TAM or RAL alone (Fig. 1a–c)o r
in combination with RA (Fig. 1d–f) demonstrate that
neither of the treatments elicits gross morphological
changes in NTera2/D1 cells compared to vehicle-
treated control cultures.
In contrast to this, Western blot analysis reveals
that TAM leads to a temporary upregulation of total
Cx43 immunoreactivity in NTera2/D1 cells with a
maximal intensity after 1 day of treatment (Fig. 2a).
This upregulation is concentration dependent result-
ing in a significant induction only in cells treated with
TAM at concentrations of 1 µmol/l and higher
(Fig. 2b, c). With regard to phosphorylation, no
signficant changes in the relative distribution of
phosphorylated and unphosphorylated forms of
Cx43 can be found (Fig. 2b).
For RAL Western blot analysis reveals also a
temporary upregulation of total Cx43 immunoreactivity
in NTera2/D1 cells; however, for this substance maxi-
mal intensity is reached after 2 days of treatment
(Fig. 3a). This upregulation is also concentration
dependent resulting in a significant induction in cells
treated with RAL at concentrations of 0.1 µmol/l and
higher (Fig. 3b, c). Also for RAL, no significant
changes in the relative distribution of phosphorylated
and unphosphorylated forms of Cx43 can be found
(Fig. 3b).
Similar results for Cx43 immunoreactivity were
obtained by immunofluorescent staining (Fig. 4a–f)
revealing a distinct increase of staining intensity in
NTera2/D1 cells by both TAM (Fig. 4a–c) and RAL
(Fig. 4d–f). In addition, a subcellular shift of Cx43
immunoreactivity can be observed with mostly
peripheral localization in untreated cells, probably
representing the cell membranes (Fig. 4a, d), and a
predominant intracellular localization in cells treated
with either TAM (Fig. 4b, c) or RAL (Fig. 4e, f).
TAM and RAL prevent the RA-dependent decrease
of Cx43 in NTera2/D1 cells
The upregulation of Cx43 immunoreactivity by
TAM and RAL in NTera2/D1 cells raises the
question, whether these substances are able to
prevent the RA-dependent reduction in Cx43
during neuronal differentiation described earlier
for these cells (Bani-Yaghoub et al. 1997; Boucher
and Bennett 2003). In order to answer this question,
NTera2/D1 cells were cotreated with 10 µmol/l RA
together with either TAM (Fig. 5a, b), or RAL
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10 µmol/l.
As Western blot analysis demonstrates, only the
highest concentration of 10 µmol/l TAM is able to
significantly diminish RA-dependent downregulation
of Cx43 in NTera2/D1 cells (Fig. 5a, b). In contrast to
this RAL is much more efficient in preventing the
RA-dependent decrease of Cx43 immunoreactivity in
NTera2/D1 cells, leading already at a concentration of
0.1 µmol/l to a significant attenuation of the RA-
dependent downregulation of Cx43 (Fig. 5c).
The results obtained by Western blot analysis are
confirmed by immunocytochemistry (Fig. 6a–f),
where cotreatment of cells with RA together with
either TAM (Fig. 6b, c) or RAL (Fig. 6e, f)i sa b l et o
induce a distinct increase in total Cx43 immunoreac-
tivity as compared to cells treated with RA alone
(Fig. 6a, d). As in the single treatments, both TAM
and RAL lead to a shift in subcellular distribution of
Cx43 immunoreactivity from a predominant
membrane-associated localization (Fig. 6a, d)t oa
preponderant staining in cytoplasmic organelles
(Fig. 6b, c, e, f).
TAM and RAL alone or together with RA lead
also to changes of functional GJ coupling
in NTera2/D1 cells
To clarify whether the changes in Cx43 expression
described above lead also to altered functional GJ
coupling, we investigated the effects of TAM and
RAL alone or in combination with RA on spreading
of the GJ permeant dye LY. As revealed by scrape
loading (Fig. 7a–f), treatment with 10 µmol/l TAM
leads to a significant increase in the spreading
distance of LY in NTera2 D1 cells, compared to
untreated controls (Fig. 7a, b, and e). In contrast,
treatment with 10 µmol/l RA results in a significant
reduction of dye spreading (Fig. 7c and e), which
cannot be observed in cells simultaneously treated
with 10 µmol/l of both RA and TAM (Fig. 7d and e).
Similar results were obtained for RAL (Fig. 7f), for
which substance a treatment at a concentration of
10 µmol/l leads to an induction of dye spreading
between NTera2/D1 cells, whereas 10 µmol/l RA
blocks functional GJ coupling. Likewise cells treated
with 10 µmol/l RA together with 10 µmol/l RAL do
not reveal a blockade of LY transfer between NTera2/
D1 cells (Fig. 7f).
Treatment of NTera2/D1 cells with TAM and RAL
during early phases of RA-dependent neural
differentiation leads to impaired neuron formation
In a final set of experiments the impact of changes in GJ
expression and function caused by TAM and RAL on
RA-inducedneuronaldifferentiationofNTera2/D1cells
was analyzed by immunocytochemical detection of the
neuronal marker protein βIII-Tubulin (Fig. 8a–h).
Cotreatment of NTera2/D1 cells during the first
abc
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Fig. 1 Phase contrast images of NTera2/D1 cells treated for
2 days with either TAM or RAL alone or in combination
with RA. a–c Cells treated with vehicle (DMSO) alone (a), or
with 10 µmol/l TAM (b) or RAL (c). d–f Cultures treated with
10 µmol/l RA alone (d) or together with 10 µmol/l TAM (e)o r
RAL (f). No gross morphological changes can be observed.
Scale bar represents 50 µm
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schedule with TAM (Fig. 8a, b, and g)o rR A L
(Fig. 8d, e, and h) results in a neuronal differentiation
defect with significantly reduced numbers of neuron
clusters and diminished neuronal process formation. In
contrast to this, cotreatment with TAM (Fig. 8c and g)
or RAL (Fig. 8f and h) during the last 2 weeks of a
6 weeks RA-induced differentiation schedule has
a
b
c
Fig. 3 Time and concentration dependency of RAL effects on
Cx43 immunoreactivity in NTera2/D1 cells as revealed by
Western blot analysis. a Densitometric evaluation of a series of
Western blots, demonstrating that in undifferentiated NTera2/
D1 cells RAL leads to a time- and concentration-dependent
increase in Cx43 immunoreactivity, reaching a maximum at
2 days of treatment. b Representative Western blot of Cx43
immunoreactivity in NTera2/D1 cells, treated for 2 days with
RAL at concentrations between 10 and 0.01 µmol/l, as depicted
by the square in (a). c Diagram of the statistical evaluation of a
series of blots as shown in (b), demonstrating a significant
upregulation of Cx43 immunoreactivity by RAL at concen-
trations of 10, 1, and 0.1 µmol/l. *p≤0.05; **p≤0.01
a
b
c
Fig. 2 Time and concentration dependency of TAM effects on
Cx43 immunoreactivity in NTera2/D1 cells as revealed by
Western blot analysis. a Densitometric evaluation of a series of
Western blots demonstrates that in undifferentiated NTera2/D1
cells, TAM leads to a time- and concentration-dependent
increase in Cx43 immunoreactivity, reaching a maximum after
a 1 day treatment. b Representative Western blot of Cx43
immunoreactivity in NTera2/D1 cells, treated for 1 day with
TAM at concentrations between 10 and 0.01 µmol/l, as
depicted by the square in (a). c Diagram of the statistical
evaluation of a series of blots as shown in (b), demonstrating a
significant upregulation of Cx43 immunoreactivity by TAM at
concentrations of 10 and 1 µmol/l. *p≤0.05; **p≤0.01
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of NTera2/D1 cells. Finally, Western blot analysis for
expression of βIII-Tubulin in NTera2/D1 cells reveals
the effects of an early treatment with TAM (Fig. 8i)o r
RAL (Fig. 8k) on expression of βIII-Tubulin in NTera2/
D1 cells to be concentration dependent.
Discussion
Results of the present study demonstrate high-dose
treatment with TAM and RAL to elicit a temporary
increase of Cx43 levels and functional GJ coupling in
NTera2/D1 cells, and to diminish the RA-dependent
downregulation of Cx43 expression and functional GJ
coupling normally observed during neuronal differen-
tiation of these cells. According to this, both
substances are able to interfere with normal neuronal
differentiation when applied during early phases of
neuronal determination, whereas already differentiat-
ed neurons are not affected. These findings therefore
confirm earlier results on the role of Cx43 and GJ
coupling during neuronal differentiation of NTera2/
D1 cells (Bani-Yaghoub et al. 1997, 1999; Boucher
and Bennett 2003) and link these effects to the actions
of TAM and RAL in these cells.
Effects of TAM on GJ coupling have been earlier
demonstrated in non-neural cell types, such as
cultured cardiac myocytes (Verrecchia and Hervé
1997), or breast cancer cells (Sáez et al. 2003). Thus,
in cultured cardiac myocytes, TAM leads to a
reduction in GJ coupling at similar concentrations
used in the present study (Verrecchia and Hervé
1997). In contrast, the human breast cancer cell line
Control TAM 10µmol/l 
RAL 10µmol/l 
TAM 1µmol/l 
Control RAL 1µmol/l 
a
d
b
e
c
f
Fig. 4 TAM- and RAL-dependent changes in subcellular
distribution of Cx43, as revealed by immunofluorescent
staining. In control cells (a, d), Cx43 immunoreactivity can
be detected both at the cell membrane (arrowheads), and in
intracellular stores (double arrows). After treatment with
10 µmol/l of either TAM (b), or RAL (e), a distinct increase
in intracellular Cx43 immunoreactivity (double arrows) can be
detected, whereas staining at the cell borders (arrowheads)
seems to be diminished. At concentrations of 1 µmol/l of either
TAM (c), or RAL (f), no gross changes in subcellular
distribution of Cx43 can be observed. Scale bar represents
10 µm
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increase in Cx expression and GJ coupling, being
probably associated with the antiproliferative effect of
TAM in these cells (Sáez et al. 2003). Obviously both
cell types display differential reaction patterns, sug-
gesting also the effects of TAM and RAL on Cx
expression and GJ coupling of the present study, to be
cell type specific.
The cell-type-specific actions of TAM and RAL on
GJ coupling, suggest specific subcellular mechanisms
to be involved. Therefore, in MCF-7 cells concentra-
tion dependency of the effects of TAM and RAL on
GJ coupling, suggests an estrogen receptor (ER)-
dependent mechanism (Sáez et al. 2003). However,
despite the fact that NTera2/D1 cells express ERs
(Chen et al. 2003; Pierson et al. 2005), the compara-
bly high concentrations of TAM and RAL necessary
to elicit changes in GJ coupling in NTera2/D1 cells,
are contradictory to a receptor-mediated mechanism.
Alternatively, the lipophilic nature of both substances
could argue for changes in membrane fluidity to
modulate intercellular GJ communication in NTera2/
D1 cells (Bennett and Verselis 1992). For TAM such
an effect has been already demonstrated in cultured
cardiac myocytes, where a reversible inhibition of GJ
coupling has been described with an IC50 of around
5 µmol/l (Verrecchia and Hervé 1997).
A mechanism which seems not to be involved in
the effects observed in NTera2/D1 cells is Cx
phosphorylation. Functionality of GJ channels con-
sisting of several Cx types such as Cx43 is regulated
by a step-wise phosphorylation, such that only
phosphorylated forms of Cx43 build functional GJ
channels (Solan and Lampe 2009). However, Western
blot results of our study do not show such a
mechanism in NTera2/D1 cells, since the increase of
total Cx43 protein by TAM and RAL is not
accompanied by a disproportional increase of the
bands representing the phosphorylated forms of Cx43.
Instead, as revealed by Western blot, the increase in
the rate of GJ coupling by TAM and RAL is probably
mostly due to an increase in total Cx43 protein
synthesis and a resulting increase in the number of
functional GJs at the cell membrane. However, as
revealed by immunocytochemistry, not all Cx43
molecules are integrated into the cell membrane, but
also subcellular localization is greatly affected by
both TAM and RAL. Thus, Cx43 seems to accumu-
late in intracellular organelles, such as the Golgi
apparatus or the trans Golgi network, as well as in
lysosomes. An argument for the latter possibility is
the small size of Cx43 immunoreactive vesicles;
however, more detailed studies with organelle-
a
b
c
Fig. 5 Western blot analysis, demonstrating that in NTera2/D1
cells, TAM and RAL are able to prevent the effects of RA on
Cx43 immunoreactivity in a concentration-dependent manner. a
Representative Western blot of Cx43 immunoreactivity in
NTera2/D1 cells treated for 1 day with either 10 µmol/l TAM
or RA alone, or with 10 µmol/l RA in combination with
different concentrations of TAM. b Diagram of the statistical
evaluation of a series of blots as shown in (a), demonstrating
the prevention of the RA-dependent decrease in Cx43 immu-
noreactivity by TAM to be highly significant. c Diagram of the
statistical evaluation of a series of blots demonstrating the pre-
vention of the RA-dependent decrease in Cx43 immunoreac-
tivity by RAL to be significant at concentrations of 0.1 µmol/l
and higher. *p≤0.05; **p≤0.01; ***p≤0.001
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clarify this point in the future.
Another important point with regard to the effects
observed in the present study, is the question whether
concentrations of TAM and RAL applied here are
within or beyond therapeutically relevant levels. On
the first glance the latter seems to be the case, since
during long-term TAM treatment, steady state serum
concentrations of up to 200 ng/ml (∼5.4×10
−8 mol/l)
were reported (Jordan 1982; Slee et al. 1988), which
are only slightly above the lowest concentrations
applied here. For RAL even lower steady-state serum
concentrations of 0.5 ng/ml have been reported
(Snyder et al. 2000; Heringa 2003). However, due to
their lipophilic properties, serum concentrations of
TAM and RAL do not always represent actual levels
in specific tissues. Thus, in human brain samples,
obtained during surgical removal of breast cancer
metastases, TAM concentrations of up to 1.5 µg per
gram of tissue weight were detected (Lien et al.
1991), suggesting that at least local concentrations of
TAM would be sufficient to modulate gap junction
coupling as it has been described here. In contrast to
that, RAL, at least in the rat brain seems not to be
locally enriched (Yang et al. 2007). This could
explain why RAL despite its obvious in vitro effects
has less brain specific side effects in patients. Never-
theless, the highest concentration of 10 µmol/l of
TAM and RAL applied here, is obviously exceeding
therapeutically relevant concentrations, and suggest
the effects observed here to be mostly of relevance for
acute toxicity.
abc
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Fig. 6 Subcellular distribution of Cx43 in NTera2/D1 cells
treated with RA alone or in combination with TAM and RAL,
as revealed by immunofluorescent staining. In cells treated with
10 µmol/l of RA alone (a, d), weak Cx43 immunoreactivity can
be detected both at the cell borders (arrowheads), and in
intracellular stores (double arrows). After treatment with
10 µmol/l of either TAM (b), or RAL (e), in combination with
10 µmol/l RA, a distinct increase in intracellular Cx43
immunoreactivity (double arrows) can be detected. NTera2/
D1 cells treated with 1 µmol/l of either TAM (c), or RAL (f),
together with 10 µmol/l RA, reveal only a slight increase in
cytoplasmic Cx43 immunoreactivity (double arrows), and,
even more important, a clear recovery of Cx43 immunoreactive
GJ plaques at the cell borders (arrowheads). Scale bar
represents 10 µm
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that TAM and RAL are able to prevent RA-dependent
downregulation of Cx43 on both expressional and
functional levels. Together with earlier findings that
RA-dependent neuronal differentiation of NTera2/D1
cells is associated with a reduction of Cx43 expres-
sion and GJ coupling (Bani-Yaghoub et al. 1997,
1999; Boucher and Bennett 2003), this suggests TAM
and RAL to interfere also with neuronal differentia-
tion of these cells. According to this, the present study
demonstrates that both TAM and RAL affect neuronal
differentiation of NTera2/D1 cells during the early
phase of RA-dependent differentiation, whereas ap-
plication during the late phase of RA treatment has no
such effect. Changes in intercellular communication
by GJ between NTera2/D1 cells elicited by TAM and
ab
cd
ef
Fig. 7 Effects of TAM or RAL alone or in combination with
RA, on spreading of the GJ permeant dye LY between NTera2/
D1 cells, as revealed by scrape loading. In control cultures of
NTera2/D1 cells (a, e), spreading of LY to cells not directly
adjacent to the scrape, can be readily detected. Treatment with
10 µmol/l TAM (b, e) clearly increases the spreading distance of
LY, whereas treatment with 10 µmol/l RA (c, e), diminishes dye
spreading between NTera2/D1 cells. Combined treatment of
NTera2/D1 cells with 10 µmol/l of each RA and TAM (d, e), is
able to restore dye spreading almost to control levels. e
Statistical evaluation of the spreading distances at 10 randomly
chosen points in each of four scrapes set in six independent
experiments, reveals the differences described above to be highly
significant. f Also a treatment of NTera2/D1 cells with 10 µmol/l
RAL, leads to an increased dye-spreading rate as compared to
normal control cells, whereas a combined treatment with
10 µmol/l of each RA and RAL, leads to a restored dye
spreading rate between NTera2/D1 cells, as compared to cells
treated with 10 µmol/l RA alone. Scale bar represents 100 µm
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Fig. 8 Effects of TAM or RAL on RA-dependent neuronal
differentiation of NTera2/D1 cells, revealed by the marker
protein βIII-Tubulin. Immunofluorescent detection of βIII-
Tubulin in NTera2/D1 cells differentiated for 6 weeks by
10 µmol/l RA (a, d) reveals strongly stained neuronal clusters
which are intensely interconnected by neuron processes. Cultures
treated with 10 µmol/l of either TAM (b) or RAL (e) during
weeks 1 and 2 of a 6 weeks RA-dependent neuronal differen-
tiation schedule, reveal reduced numbers of βIII-Tubulin
positive neuron clusters, as well as decreased neuronal process
formation. In contrast, cultures treated with 10 µmol/l of either
TAM (c)o rR A L( f) during weeks 5 and 6, are almost
indistinguishable from the control cultures treated with RA
alone. g, h Statistical evaluation of a set of eight independent
experiments as shown in a–f, revealing the effects of TAM (g)
and RAL (h), to be highly significant. i, k Western blot analysis
for βIII-Tubulin in NTera2/D1 cells treated with different
concentrations of either TAM (i) or RAL (k) during the first
2 weeks of a 6 weeks RA-dependent differentiation schedule.
Actions of both substances are obviously concentration depen-
dent. Scale bar represents 25 µm
Cell Biol Toxicol (2010) 26:579–591 589RAL seems therefore not to affect differentiated
neurons in the mature brain, however, might be of
importance for an understanding of effects of TAM
and RAL during early nervous system formation in
the embryo.
In several brain lesion paradigms, such as middle
cerebral artery occlusion (Mehta et al. 2003)o r
permanent focal ischemia (Kimelberg et al. 2003),
TAM has been shown to act neuroprotective and
upregulation of GJ intercellular communication plays
a role for these effects (Hossain et al. 1994; Nakase et
al. 2003). This seems on the first glance to be
contradictory to our findings. However, as discussed
before, the effects described here are observed only
during early phases of neuronal differentiation,
whereas in later phases, TAM and RAL are no longer
able to impair neuronal differentiation and function-
ing. Whether under these circumstances TAM or RAL
act in a protective manner has not been addressed by
the present study and therefore remains to be clarified
in the future.
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